Neutrophil-to-Lymphocyte Ratio May Predict Thrombotic Events in Polycythemia Vera
Researchers sought to determine whether neutrophil-to-lymphocyte ratio would be predictive of thrombotic events in patients with polycythemia vera.
Diagnosis & Disease Information
Link Found Between Anti-Endothelial Cell Antibodies and Thrombosis With Polycythemia Vera
Researchers sought to determine whether there was a link between anti-endothelial cell antibodies and thrombosis in patients with polycythemia vera.
Rusfertide for Patients With Phlebotomy-Dependent Polycythemia Vera
Rusfertide demonstrated activity in reducing hematocrit levels in patients with polycythemia vera in two phase 2 clinical trials.
Momelotinib Demonstrates Superiority Over Danazol in Thrombocytopenic Myelofibrosis
Researchers sought to compare the efficacy of momelotinib with danazol in patients with thrombocytopenic myelofibrosis who were symptomatic and anemic.
The Effect of Gender Bias in Surveys of Patients With Myeloproliferative Neoplasm
Gender balance in cancer surveys of patients with myeloproliferative neoplasms was found to have relatively little effect on survey outcomes.
Interferon-Alpha and Hydroxyurea Show Efficacy in Polycythemia Vera and Essential Thrombocythemia
Researchers sought to determine whether interferon-alpha or hydroxyurea would be effective treatments for patients with essential thrombocythemia and polycythemia vera.
Risk Factors for Thrombosis Identified in Post-Polycythemia Vera Myelofibrosis
Findings from a retrospective study identified risk factors for thrombosis in patients with post-polycythemia vera myelofibrosis, compared with patients with polycythemia vera.
Bleeding Risks in Patients With MPNs Increased With Anticoagulant Use, Antiplatelet Therapy
Multivariate analysis of patients with MPNs receiving antiplatelet or anticoagulation therapy revealed an increase in risk of bleeding events in these patients.
Besremi Approved for Adults With Polycythemia Vera
Besremi is a monopegylated, long-acting interferon, which exhibits its cellular effects in the bone marrow in polycythemia vera.
How Can Lifestyle Factors Affect Myeloproliferative Neoplasms?
As myeloproliferative neoplasms (MPN) are a particularly rare form of blood cancer without a clear cause, it may be difficult to understand how lifestyle factors can affect both MPN risk and symptom burden. What has research suggested about the ways certain lifestyle factors affect MPNs?
- Loading...
Loading...
Next post in Myelodysplastic Syndromes
Loading... 
Loading...